Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
Luca Gianni1, Urania Dafni2, Richard D Gelber3, Evandro Azambuja4, Susanne Muehlbauer5, Aron Goldhirsch6,7, Michael Untch8, Ian Smith9, José Baselga10, Christian Jackisch11, David Cameron12, Max Mano13, José Luiz Pedrini14, Andrea Veronesi15, Cesar Mendiola16, Anna Pluzanska17, Vladimir Semiglazov18, Eduard Vrdoljak19, Michael J Eckart20, Zhenzhou Shen21
1Department of Medical Oncology, San Raffaele Institute, Milan, Italy
2Laboratory of Biostatistics, University of Athens, and Frontier Science Foundation-Hellas, Athens, Greece
3Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA
4Medical Oncology Clinic and Breast European Adjuvant Study Team (BrEAST) Data Centre, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium
5F. Hoffmann-La Roche, Basel, Switzerland
6Department of Medicine, European Institute of Oncology, Milan, Italy
7Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
8Department of Gynaecology and Obstetrics and Multidisciplinary Breast Cancer Center, Helios Klinikum Berlin-Buch, Germany
9Breast Unit, Royal Marsden Hospital, and Institute of Cancer Research, London, UK
10Division of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA
11Department of Gynecology and Obstetrics, Klinikum Offenbach, Germany
12University of Edinburgh and Department of Oncology, Western General Hospital, Edinburgh, UK
13Department of Medical Oncology at the Instituto do Câncer do Estado de São Paulo, University of São Paulo, Brazil
14Unity of Mastology of Hospital Nossa Senhora da Conceição, Ministério da Saude, Brazil
15Division of Medical Oncology C, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy
16Médicos Colaboradores en Oncología Médica, Hospital Ruber Internacional, Madrid, Spain
17Oncological Chemotherapy Clinic, Regional Oncology Centre, Lodz, Poland
18Petrov Research Institute of Oncology, St Petersburg, Russian Federation
19University Hospital Split, Split, Croatia
20Onkologische Schwerpunktpraxis und Tagesklinik, Erlangen, Germany
21Cancer Hospital, Fudan University, Shanghai, China
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
The Lancet Oncology
Tập 12
236-244
Thông tin tác giả